Lithium increases dynorphin A(1-8) and prodynorphin mRNA levels in the basal ganglia of rats

Subbiah Sivam, K. Takeuchi, S. Li, J. Douglass, O. Civelli, L. Calvetta, E. Herbert, J. F. McGinty, J. S. Hong

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

The aim of this study was to understand the possible influence of the antimanic drug, lithium, and the neuroleptic, haloperidol, alone or in combination, on the regulation of dynorphin biosynthesis in the striatum. The study was done using male Fisher-344 rats subjected to a regimen of subchronic administration of lithium chloride (4 mEq/kg/day for 1, 2, 4 or 6 days, i.p.) or a regimen of chronic oral administration of a diet containing lithium carbonate (1.5 g/kg of the diet). Subchronic administration of lithium increased striatal dynorphin A(1-8)-like immunoreactivity (DN-LI) in a time-related fashion. Immunocytochemistry revealed an increase in DN-LI in fibers and cells clustered in 'patches' throughout striatum. The increase in DN-LI was reversible on cessation of lithium administration. Concurrent administration of lithium and an opiate antagonist, naltrexone, or a dopamine receptor antagonist, haloperidol, did not influence the changes induced by lithium. Chronic oral administration of lithium for 21 days led to an increase in DN-LI in the striatum. Co-administration of haloperidol with the 21 day regimen of lithium administration failed to affect the increase in DN-LI. The prodynorphin mRNA abundance in the striatum was quantitated by a molecular hybridization procedure using a prodynorphin 32P-cRNA probe generated from the Riboprobe system. Evidence from the Northern blot analysis reveals that lithium increases the prodynorphin mRNA abundance in the striatum. These results indicate that lithium affects the dynamics of prodynorphin biosynthesis in the striatum, presumably increasing transcription and/or translational processes.

Original languageEnglish
Pages (from-to)155-163
Number of pages9
JournalMolecular Brain Research
Volume3
Issue number2
DOIs
StatePublished - 1988

Fingerprint

dynorphin (1-8)
Basal Ganglia
Lithium
Messenger RNA
Haloperidol
Oral Administration
Opiate Alkaloids
Antimanic Agents
Diet
Lithium Carbonate
Lithium Chloride
preproenkephalin
Corpus Striatum
Dynorphins
Complementary RNA
Naltrexone
Dopamine Antagonists

Keywords

  • Dynorphin
  • Haloperidol
  • Lithium
  • Naltrexone
  • Prodynorphin messenger ribonucleic acid (mRNA)

ASJC Scopus subject areas

  • Molecular Biology
  • Cellular and Molecular Neuroscience

Cite this

Lithium increases dynorphin A(1-8) and prodynorphin mRNA levels in the basal ganglia of rats. / Sivam, Subbiah; Takeuchi, K.; Li, S.; Douglass, J.; Civelli, O.; Calvetta, L.; Herbert, E.; McGinty, J. F.; Hong, J. S.

In: Molecular Brain Research, Vol. 3, No. 2, 1988, p. 155-163.

Research output: Contribution to journalArticle

Sivam, S, Takeuchi, K, Li, S, Douglass, J, Civelli, O, Calvetta, L, Herbert, E, McGinty, JF & Hong, JS 1988, 'Lithium increases dynorphin A(1-8) and prodynorphin mRNA levels in the basal ganglia of rats', Molecular Brain Research, vol. 3, no. 2, pp. 155-163. https://doi.org/10.1016/0169-328X(88)90061-7
Sivam, Subbiah ; Takeuchi, K. ; Li, S. ; Douglass, J. ; Civelli, O. ; Calvetta, L. ; Herbert, E. ; McGinty, J. F. ; Hong, J. S. / Lithium increases dynorphin A(1-8) and prodynorphin mRNA levels in the basal ganglia of rats. In: Molecular Brain Research. 1988 ; Vol. 3, No. 2. pp. 155-163.
@article{552c26bc863648c492c5f39ef6572e80,
title = "Lithium increases dynorphin A(1-8) and prodynorphin mRNA levels in the basal ganglia of rats",
abstract = "The aim of this study was to understand the possible influence of the antimanic drug, lithium, and the neuroleptic, haloperidol, alone or in combination, on the regulation of dynorphin biosynthesis in the striatum. The study was done using male Fisher-344 rats subjected to a regimen of subchronic administration of lithium chloride (4 mEq/kg/day for 1, 2, 4 or 6 days, i.p.) or a regimen of chronic oral administration of a diet containing lithium carbonate (1.5 g/kg of the diet). Subchronic administration of lithium increased striatal dynorphin A(1-8)-like immunoreactivity (DN-LI) in a time-related fashion. Immunocytochemistry revealed an increase in DN-LI in fibers and cells clustered in 'patches' throughout striatum. The increase in DN-LI was reversible on cessation of lithium administration. Concurrent administration of lithium and an opiate antagonist, naltrexone, or a dopamine receptor antagonist, haloperidol, did not influence the changes induced by lithium. Chronic oral administration of lithium for 21 days led to an increase in DN-LI in the striatum. Co-administration of haloperidol with the 21 day regimen of lithium administration failed to affect the increase in DN-LI. The prodynorphin mRNA abundance in the striatum was quantitated by a molecular hybridization procedure using a prodynorphin 32P-cRNA probe generated from the Riboprobe system. Evidence from the Northern blot analysis reveals that lithium increases the prodynorphin mRNA abundance in the striatum. These results indicate that lithium affects the dynamics of prodynorphin biosynthesis in the striatum, presumably increasing transcription and/or translational processes.",
keywords = "Dynorphin, Haloperidol, Lithium, Naltrexone, Prodynorphin messenger ribonucleic acid (mRNA)",
author = "Subbiah Sivam and K. Takeuchi and S. Li and J. Douglass and O. Civelli and L. Calvetta and E. Herbert and McGinty, {J. F.} and Hong, {J. S.}",
year = "1988",
doi = "10.1016/0169-328X(88)90061-7",
language = "English",
volume = "3",
pages = "155--163",
journal = "Brain Research",
issn = "0006-8993",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Lithium increases dynorphin A(1-8) and prodynorphin mRNA levels in the basal ganglia of rats

AU - Sivam, Subbiah

AU - Takeuchi, K.

AU - Li, S.

AU - Douglass, J.

AU - Civelli, O.

AU - Calvetta, L.

AU - Herbert, E.

AU - McGinty, J. F.

AU - Hong, J. S.

PY - 1988

Y1 - 1988

N2 - The aim of this study was to understand the possible influence of the antimanic drug, lithium, and the neuroleptic, haloperidol, alone or in combination, on the regulation of dynorphin biosynthesis in the striatum. The study was done using male Fisher-344 rats subjected to a regimen of subchronic administration of lithium chloride (4 mEq/kg/day for 1, 2, 4 or 6 days, i.p.) or a regimen of chronic oral administration of a diet containing lithium carbonate (1.5 g/kg of the diet). Subchronic administration of lithium increased striatal dynorphin A(1-8)-like immunoreactivity (DN-LI) in a time-related fashion. Immunocytochemistry revealed an increase in DN-LI in fibers and cells clustered in 'patches' throughout striatum. The increase in DN-LI was reversible on cessation of lithium administration. Concurrent administration of lithium and an opiate antagonist, naltrexone, or a dopamine receptor antagonist, haloperidol, did not influence the changes induced by lithium. Chronic oral administration of lithium for 21 days led to an increase in DN-LI in the striatum. Co-administration of haloperidol with the 21 day regimen of lithium administration failed to affect the increase in DN-LI. The prodynorphin mRNA abundance in the striatum was quantitated by a molecular hybridization procedure using a prodynorphin 32P-cRNA probe generated from the Riboprobe system. Evidence from the Northern blot analysis reveals that lithium increases the prodynorphin mRNA abundance in the striatum. These results indicate that lithium affects the dynamics of prodynorphin biosynthesis in the striatum, presumably increasing transcription and/or translational processes.

AB - The aim of this study was to understand the possible influence of the antimanic drug, lithium, and the neuroleptic, haloperidol, alone or in combination, on the regulation of dynorphin biosynthesis in the striatum. The study was done using male Fisher-344 rats subjected to a regimen of subchronic administration of lithium chloride (4 mEq/kg/day for 1, 2, 4 or 6 days, i.p.) or a regimen of chronic oral administration of a diet containing lithium carbonate (1.5 g/kg of the diet). Subchronic administration of lithium increased striatal dynorphin A(1-8)-like immunoreactivity (DN-LI) in a time-related fashion. Immunocytochemistry revealed an increase in DN-LI in fibers and cells clustered in 'patches' throughout striatum. The increase in DN-LI was reversible on cessation of lithium administration. Concurrent administration of lithium and an opiate antagonist, naltrexone, or a dopamine receptor antagonist, haloperidol, did not influence the changes induced by lithium. Chronic oral administration of lithium for 21 days led to an increase in DN-LI in the striatum. Co-administration of haloperidol with the 21 day regimen of lithium administration failed to affect the increase in DN-LI. The prodynorphin mRNA abundance in the striatum was quantitated by a molecular hybridization procedure using a prodynorphin 32P-cRNA probe generated from the Riboprobe system. Evidence from the Northern blot analysis reveals that lithium increases the prodynorphin mRNA abundance in the striatum. These results indicate that lithium affects the dynamics of prodynorphin biosynthesis in the striatum, presumably increasing transcription and/or translational processes.

KW - Dynorphin

KW - Haloperidol

KW - Lithium

KW - Naltrexone

KW - Prodynorphin messenger ribonucleic acid (mRNA)

UR - http://www.scopus.com/inward/record.url?scp=0023895456&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023895456&partnerID=8YFLogxK

U2 - 10.1016/0169-328X(88)90061-7

DO - 10.1016/0169-328X(88)90061-7

M3 - Article

VL - 3

SP - 155

EP - 163

JO - Brain Research

JF - Brain Research

SN - 0006-8993

IS - 2

ER -